PDSnetSA

Our opinion on the current state of NVS

JSE:NVS   NOVUS HOLDINGS LIMITED
Novus (NVS) is South Africa's largest printing company with 11 printing plants. Until recently, it had the monopoly contract to do all of Media24's printing. With effect from 1-4-18, that contract was reduced to roughly 58% of Media24's printing and the price paid by Media24 for printing was also reduced. The company appointed a new CEO, Neil Birch, who has decided in the short term to abandon the company's acquisitions and focus on consolidating the business and improving its operating performance. The board may also look to sell the company's tissue business. The company has a level 4 BEE status but will need to improve that to become more competitive. On 12th August 2022 the company announced that it would acquire 75% of Pearson South Africa. In its results for the six months to 30th September 2023 the company reported revenue up 36,8% and headline earnings per share (HEPS) of 28,77c compared with 2,89c in the previous period. The company said, "The financial results for the six months ended 30 September 2023 ("period") improved when compared to the prior period, largely through the inclusion of the results of Maskew Miller Learning Proprietary Limited ("MML") in the Education segment". Technically, the share price fell steadily since listing in March 2015 until March 2021. Then it began to move up and it currently trades at 54% of its NAV. We suggested waiting for a convincing break up through a 65-day moving average before investigating further. That has happened on 8-10-20 at 88c and the share has since moved up to 421c. The share trades about R263 000 worth of shares a day which makes it practical for private investors.

Top 3 & 4 companies on our winning shares list.
Snapshot: 4/2024

#3 - MIXTEL- MIX- Added 2023-12-28 - 86.44% Gain since added
#4 - HARMONY - HAR- Added 2023-11-16 - 70.15% Gain since added

Full list available to PDSnet subscribers only.
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.